The Business of Fashion
Agenda-setting intelligence, analysis and advice for the global fashion community.
Agenda-setting intelligence, analysis and advice for the global fashion community.
Rhode, the skincare line of Hailey Bieber, has named Lauren Ratner as its new president and chief brand officer.
Ratner, formerly head of brand, has been promoted to the role following the departure of chief executive officer Melanie Bender in October. It’s unclear if the company intends to appoint a new chief executive at this time.
Ratner has worked with Rhode since 2020, before the brand’s launch, having previously held marketing positions at Reformation and Michael Kors. She’s played a role in forging unexpected partnerships such as Rhode’s tie-up with Krispy Kreme (the companies released a limited edition version of her popular Peptide Lip Treatment in a doughnut-inspired flavour).
Rhode, which launched in 2022 with a small range of skin care products, has recently started to experiment with colour cosmetics. It launched a range of tinted lip products in September, as well as a sparkly edition in November.
ADVERTISEMENT
This appointment comes amid a series of leadership shakeups at Rhode. Claudia Allwood, founding CMO, left last year after joining in October 2021 and Iván Saragusti, the brand’s founding COO, departed in January 2022.
Editor’s Note: This story was updated on December, 5, 2023, to amend the date of Bender’s departure and the launch date of the tinted Peptide Lip Treatment.
Learn more:
Hailey Bieber Looks to Beat Beauty Brand Fatigue With Rhode Label
In a market oversaturated with celebrity beauty brands, Hailey Bieber says her brand is “different” from others.
This month, BoF Careers provides essential sector insights to help beauty professionals decode the industry’s creative landscape.
The skincare-to-smoothie pipeline arrives.
Puig and Space NK are cashing in on their ability to tap the growth of hot new products, while L’Occitane, Olaplex and The Estée Lauder Companies are discovering how quickly the shine can come off even the biggest brands.
Demand for the drugs has proven insatiable. Shortages have left patients already on the medications searching for their next dose and stymied new starters.